Loading…
Lobbying Spend
—
Filings
9
Firms Hired
1
Active Period
2020–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Medical Nutrition Equity Act of 2019
2020 · fourth_quarter · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $20,000
Matched citations: HR 2501
Newborn Screening Saves Lives Reauthorization Act of 2019
2020 · fourth_quarter · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $20,000
Matched citations: H.R. 2507
Advancing Access to Precision Medicine Act
2020 · fourth_quarter · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $20,000
Matched citations: H.R. 4393
Genome Editing Threat Assessment Act
2020 · fourth_quarter · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $20,000
Matched citations: H.R. 8045
The Newborn Screening Saves Lives Reauthorization Act of 2019
2020 · fourth_quarter · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $20,000
Matched citations: S. 2158
Medical Nutrition Equity Act of 2019
2020 · third_quarter · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $10,000
Matched citations: HR 2501
Newborn Screening Saves Lives Reauthorization Act of 2019
2020 · third_quarter · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $10,000
Matched citations: H.R. 2507
Advancing Access to Precision Medicine Act
2020 · third_quarter · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $10,000
Matched citations: H.R. 4393
Genome Editing Threat Assessment Act
2020 · third_quarter · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $10,000
Matched citations: H.R. 8045
The Newborn Screening Saves Lives Reauthorization Act of 2019
2020 · third_quarter · Firm: BURRELL INTERNATIONAL GROUP LLC
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: — · Firm income: $10,000
Matched citations: S. 2158
Source: Senate LDA